Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

This study is testing an intensive treatment approach for a type of esophageal or stomach cancer, combining immunotherapy, surgery or radiation, and a drug called durvalumab (an immune checkpoint inhibitor that helps the immune system fight cancer). **You may be eligible if...** - You have been diagnosed with esophageal or gastroesophageal junction cancer - Your cancer has not yet spread to distant parts of the body - You are healthy enough to tolerate surgery, chemotherapy, and immunotherapy - You meet the staging and tissue type requirements **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have autoimmune conditions that could be worsened by immunotherapy - You have had prior treatment for this cancer - Your organ function is too impaired to handle the treatment plan Talk to your doctor to see if this trial is right for you.